Metastatic squamous cell carcinoma

This phase II trial is testing whether the combination of cabozantinib (a targeted therapy) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head and neck cancers that have stopped responding to prior immunotherapy. Researchers are also checking if t…

This study tests whether adding cetuximab to standard immunotherapy (pembrolizumab) helps people with advanced head and neck cancer that has stopped responding to platinum chemotherapy live longer. About 158 adults with cancer that has returned or spread will receive either pembr…

This phase 2 trial tests an experimental drug called ficerafusp alfa, which targets two proteins that help tumors grow, when given with the immunotherapy pembrolizumab. The study enrolls adults with recurrent or metastatic head and neck squamous cell carcinoma that has not been t…

This study tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with two anti-rejection medications (sirolimus and prednisone) in kidney transplant recipients who have advanced skin cancer that cannot be surgically removed or has spread. The goal is to …

This early-phase trial tests a new drug called STC-15, either alone or combined with an immunotherapy drug (toripalimab), in people with advanced solid tumors or certain sarcomas. The study aims to check safety and whether the drugs shrink tumors. About 107 participants will be e…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This phase 2 trial is testing a combination of three therapies—modified immune cells (PD-L1 t-haNK), an immune-boosting protein (NAI/Anktiva), and a targeted antibody (cetuximab)—in 25 people with recurrent or metastatic head and neck cancer that has not responded to prior immuno…

This study tests whether adding an experimental drug called ficerafusp alfa to the immunotherapy pembrolizumab (Keytruda) works better than pembrolizumab alone for people with PD-L1-positive head and neck cancer that has spread or returned. About 650 adults will be randomly assig…

This study compares two ways of giving the chemotherapy drug 5-FU to people with head and neck cancer that has spread or come back after prior treatments. One group gets the drug over two days every two weeks, the other over four days every three weeks. The goal is to see which s…

This trial is testing a new approach for people with head and neck cancer that has come back or spread and cannot be removed. It combines a device called DaRT, which is a tiny radioactive seed placed directly into the tumor, with the immunotherapy drug pembrolizumab (Keytruda). T…

This early-phase trial tests a personalized vaccine made from a patient's own tumor cells, given alone or with the immunotherapy drug pembrolizumab, for people with head and neck cancer that has returned or spread. The main goals are to check safety, find the best dose, and see i…

This phase II trial tests whether adding lovastatin, a common cholesterol-lowering drug, to the immunotherapy pembrolizumab can help shrink tumors in people with head and neck cancer that has returned or spread. The study will enroll 28 adults whose tumors express PD-L1. Research…

This study tests a treatment using a patient's own immune cells (called tumor-infiltrating lymphocytes or TILs) combined with chemotherapy and interleukin-2 for people with advanced cutaneous squamous cell carcinoma or Merkel cell carcinoma who have already tried immunotherapy. T…

This early-stage trial is testing a new three-drug combination for people with head and neck cancer that has come back or spread. The drugs include a targeted therapy (zanzalintinib), an immunotherapy (pembrolizumab), and another targeted antibody (cetuximab). The main goal is to…

This phase 2 trial tests whether adding olanzapine to standard care helps manage appetite loss in head and neck cancer patients undergoing chemoradiation. About 66 adults will receive either olanzapine plus standard symptom management or standard care alone. The main goal is to s…

This study looks at whether getting immunotherapy infusions in the morning versus the afternoon changes outcomes for people with advanced lung cancer or head and neck cancer. About 238 participants will be randomly assigned to morning or afternoon infusions. Researchers will trac…

This study tests whether offering hearing tests close to home or remotely increases how many head and neck cancer patients get their hearing checked during treatment. Many patients on cisplatin chemotherapy or radiation near the ear can lose hearing, but not all complete recommen…